Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.
about
Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Circulating immune cell phenot ...... ory/relapsed multiple myeloma.
@en
Circulating immune cell phenot ...... ory/relapsed multiple myeloma.
@nl
type
label
Circulating immune cell phenot ...... ory/relapsed multiple myeloma.
@en
Circulating immune cell phenot ...... ory/relapsed multiple myeloma.
@nl
prefLabel
Circulating immune cell phenot ...... ory/relapsed multiple myeloma.
@en
Circulating immune cell phenot ...... ory/relapsed multiple myeloma.
@nl
P2093
P2860
P1476
Circulating immune cell phenot ...... ory/relapsed multiple myeloma.
@en
P2093
Byung-Sik Cho
Chang-Ki Min
Da-Bin Ryu
Dong-Wook Kim
Hee-Je Kim
Jae-Ho Yoon
Ji-Young Lim
Jong-Wook Lee
Ki-Seong Eom
Myungshin Kim
P2860
P2888
P304
P356
10.1007/S00262-016-1861-2
P577
2016-06-24T00:00:00Z